Introduction
============

Uveitis is characterized by intraocular inflammatory disease and can be caused by infectious or non-infectious mechanisms. This immune-mediated disease has occasional systemic involvement and is an important cause of blindness \[[@r1],[@r2]\]. Two important uveitis entities with systemic involvement are Vogt-Koyanagi-Harada (VKH) syndrome and Behçet's disease (BD). VKH syndrome is characterized by bilateral ocular involvement, sunset glow fundus, choroiditis, headache, tinnitus, dysacusis, neck rigidity, pleocytosis, alopecia, leukotrichia, and vitiligo \[[@r3]\]. VKH syndrome mainly occurs in individuals with dark skin pigmentation, such as Asians, Native Americans, and Hispanics and is rare in Caucasians. Several studies have suggested that the *HLA-DR4*(Gene ID: 3126), *HLA-DRB1/DQA1*(Gene ID: 3123, OMIM: [142857](http://omim.org/entry/142857)), *CTLA-4*(Gene ID: 1493, OMIM:[123890](http://omim.org/entry/123890)), *IL-*17F (Gene ID: 112744, OMIM: [606496](http://omim.org/entry/606496)), *miRNA-182*(Gene ID: 406958, OMIM: [611607](http://omim.org/entry/611607)), and *FAS*(Gene ID: 355, OMIM: [134637](http://omim.org/entry/134637)) genes are associated with VKH syndrome \[[@r4]-[@r9]\]. BD is characterized by recurrent uveitis, eye lesions, skin lesions, positive pathergy test, retinal vasculitis, arthritis, and oral and genital mucous ulcers. BD mainly occurs in countries along the ancient Silk Road with a frequency of 80--370 cases per 100,000 population in Turkey and 10/100,000 in Japan and is not common in Caucasians (0.6/100,000 in the United Kingdom) \[[@r10]\]. The exact reason for this situation is not yet clear, but it might be caused by environmental factors. Additionally, a local genetic predisposition may play an important role. Previous studies have shown that *HLA* genes, such as *HLA-B51 (*Gene ID: 3106, OMIM:[142830](http://omim.org/entry/142830)), non-HLA genes, such as *IL23R*(Gene ID: 149233, OMIM: [607562](http://omim.org/entry/607562))-*IL12RB2*(Gene ID: 3595, OMIM: [601642](http://omim.org/entry/601642)), *IL-10*(Gene ID: 3586, OMIM: [124092](http://omim.org/entry/124092)), *STAT4*(Gene ID: 6775, OMIM: [600558](http://omim.org/entry/600558)), *miRNA-146a*(Gene ID: 406938, OMIM: [610566](http://omim.org/entry/610566)), *DHCR7*(Gene ID: 1717, OMIM: [602858](http://omim.org/entry/602858)), *PDGFRL*(Gene ID: 5157, OMIM: [604584](http://omim.org/entry/604584)), *miRNA-182*, and *FAS* genes predispose individuals to the occurrence of BD \[[@r8],[@r9],[@r11]-[@r16]\].

Since uveitis often leads to visual impairment, it is essential to control the intraocular inflammation as soon as possible. Research directed at unraveling the various pathways of inflammation operative in the eye may lead to new therapies. The analysis of immunogenetic associations with uveitis may help to identify the role of various inflammatory or immune response--related factors in this disease. Gene polymorphisms that have recently received a great deal of attention in the pathogenesis of autoimmune disease include the nitric oxide synthase (NOS) family. NOS catalyzes the production of NO from L-arginine. The NOS family has three well-known isoforms: neuronal NOS (nNOS, NOS1, Gene ID: 4842, OMIM: [163731](http://omim.org/entry/163731)), inducible NOS (iNOS, NOS2, Gene ID: 4843, OMIM: [163730](http://omim.org/entry/163730)), and endothelial (eNOS, NOS3, Gene ID: 4846, OMIM: [163729](http://omim.org/entry/163729)). NOS1 and NOS3 can rapidly produce small amounts of NO. Its function is mostly physiologic and is short-lived. However, NOS2 produces large amounts of potentially toxic NO that can persist for longer periods \[[@r17]\]. NO generated by NOS2 is important in immune processes and is increased after chronic inflammatory and immunologic stimuli. Its cytotoxic and cytostatic effects can attack abnormal and healthy cells \[[@r18]\]. Various studies have addressed the role of *NOS1*, *NOS2*, and *NOS3* polymorphisms in a large number of autoimmune diseases, such as BD \[[@r19]\], rheumatoid arthritis \[[@r20]\], systemic lupus erythematosus \[[@r21]\], type 1 diabetes mellitus \[[@r22]\], multiple sclerosis \[[@r23]\], psoriasis \[[@r24]\], vitiligo \[[@r17]\], and non-Hodgkin's lymphoma \[[@r25]\].

The role of *NOS* gene polymorphisms has not yet been reported in patients with uveitis and was therefore the subject of the study presented here. We chose two relatively common uveitis entities observed in China to obtain a sufficient sample size, BD and VKH syndrome. In this study, the potential association of *NOS2*/[rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067) (intronic variant), *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) (coding variant), and *NOS3*/[rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779) (intronic variant) polymorphisms with VKH syndrome and BD was investigated in a Han Chinese population. Of the combinations tested, only [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) was shown to be significantly involved in the genetic susceptibility of BD in Han Chinese.

Methods
=======

Case--control cohorts
---------------------

A case--control study was performed including 733 patients with BD, 800 patients with VKH syndrome, and 1,359 healthy controls. All patients and controls were Han Chinese and were recruited at the Zhongshan Ophthalmic Center of Sun Yat-sen University (Guangzhou, China) and the First Affiliated Hospital of Chongqing Medical University (Chongqing, China) from April 2005 to November 2014. The diagnosis of BD and VKH syndrome was based on the criteria of the International Study Group for BD \[[@r26]\] and VKH syndrome \[[@r27]\], respectively. All participants provided written informed consent, and the study was approved by the Clinical Research Ethics Committee of the Zhongshan Ophthalmic Center of Sun Yat-sen University and the First Affiliated Hospital of Chongqing Medical University (Permit Number: 2009--201008) and adhered to the tenets of the Declaration of Helsinki as well as the ARVO statement on human subjects.

Genotyping
----------

Peripheral blood from the patients and controls was obtained from the elbow vein, collected in vacuum blood tubes with EDTA, and cryopreserved at −20 °C. DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen Inc., Hilden, Germany) according to the manufacturer's instructions. Single nucleotide polymorphism (SNP) genotyping was performed using the PCR restriction fragment length polymorphism (PCR-RFLP) method. The 7 µl PCR mixtures contained 10 ng of DNA, 0.25 µM of each primer, 3 µl Gotaq® Green Master Mix (Promega, Madison, WI), and 2 µl Nuclease-Free Water (Promega). The PCR amplification conditions were as follows: 95 °C for 5 min, 37--43 cycles of 95 °C for 30 s, 58--65 °C for 30 s, extension at 72 °C for 30 s, and a final extension at 72 °C for 10 min, following storage at 4 °C ([Table 1](#t1){ref-type="table"}). The PCR products (7 µl) were digested with 3U restriction endonuclease ([Table 1](#t1){ref-type="table"}) and incubated at 37 °C for 16 h. The digested fragments were analyzed with electrophoresis on a 4% agarose gel, which were stained with GoldView™ (SBS Genetech, Beijing, China). DNA bands were analyzed by Vilber Lourmat (Marne la Vallée, France) under ultraviolet (UV) light. Approximately 5% of the samples were randomly selected for direct sequencing to check the accuracy of the PCR-RFLP method used in the study. All SNPs tested in the study showed a genotyping success rate greater than or equal to 95% and accuracy greater than 99% in the case and control groups.

###### Primers, restriction enzymes and PCR conditions used to analyze the nitric oxide synthase (NOS)2 and NOS3 polymorphism.

  Gene          SNP ID                      Primer (5'-3')                 Restriction enzyme   Restriction fragment   Tm (°C)
  ------------- --------------------------- ------------------------------ -------------------- ---------------------- ---------
  NOS2          rs4795067                   F: TAATCCCAGCCAGAGAGA CG       KspAI                A:117                  64
  (iNOS)                                    R: AGCCTGGCACATACTTGAAGGTTAA   (MBI)                G:23, 94bp             
  NOS3 (eNOS)   rs1799983                   F: CATGAGGCTCAGCCCCAGAA        SduI                 T:206bp G:124, 82bp    60
                R: AGTCAATCCCTTTGGTGCTCAC   (MBI)                                                                      
  rs1800779     F: TCTGCCTCTCCCAGTCTCTCA    BccI                           A:189bp              65                     
                R: AGCACTCTCCAGGCACTTCAG    (NEB)                          G:124,65bp                                  

Statistical analysis
--------------------

[SHEsis](http://analysis.bio-x.cn/myAnalysis.php) software was used to test whether the experimental data were in accordance with Hardy--Weinberg equilibrium. The chi-square test was used to compare the genotype and allele frequencies between patients and controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated with SPSS version 17.0 (Chicago, IL). To account for multiple testing, p values were corrected with the Bonferroni correction (Pc). A Pc of less than 0.05 was considered statistically significant.

Results
=======

Clinical features of patients with BD and patients with VKH syndrome
--------------------------------------------------------------------

The detailed clinical characteristics of the patients with BD, patients with VKH syndrome, and healthy controls are shown in [Table 2](#t2){ref-type="table"}. The genotype frequencies of [rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067)and [rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779) were in accordance with the Hardy--Weinberg equilibrium in the controls (χ2=2.97, p=0.09; χ2=1.92, p=0.17, respectively). However, it appeared that rs1799983 deviated from the Hardy--Weinberg equilibrium (p\<0.05).

###### The clinical features in BD patients, VKH syndrome patients and healthy controls.

  Disease                      Clinical features        Total       \%
  ---------------------------- ------------------------ ----------- ------
  Patients with BD                                      733         100
                               Mean age ±SD             29.6±10.2    
                               Male                     628         85.7
                               Female                   105         14.3
                               Uveitis                  733         100
                               Oral ulcer               733         100
                               Genital ulcer            410         55.9
                               Skin lesions             526         71.8
                               Arthritis                115         15.7
                               Positive pathergy test   167         22.8
                               Retinal vasculitis       40          5.5
  Patients with VKH syndrome                            800          
                               Mean age ±SD             38.0±12.3    
                               Male                     442         55.3
                               Female                   358         44.7
                               Uveitis                  800         100
                               Sunset-like eyes         451         56.4
                               Neck stiffness           88          22
                               Headache                 329         41.1
                               Tinnitus                 367         45.9
                               Hearing loss             258         32.2
                               Vitiligo                 140         17.5
                               Alopecia                 311         38.9
                               Poliosis                 296         37
  Controls                                              1359         
                               Mean age±SD              39.1±10.8    
                               Male                     762         56.1
                               Female                   597         43.9

The genotype and allele frequency distribution of NOS2 and NOS3 in BD and VKH syndrome
--------------------------------------------------------------------------------------

Genotyping for the three SNPs in the patients with BD, patients with VKH, and healthy controls was performed with PCR-RFLP. The results showed that the genotype frequencies of *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) were significantly different between the patients with BD and the healthy controls (Appendix 1, Figure S1, [Table 3](#t3){ref-type="table"}). The frequency of the heterozygous GT genotype was significantly higher in patients with BD (Pc=2.1×10^−3^, OR=1.57; [Table 3](#t3){ref-type="table"}). No statistical differences for the genotype and allele frequencies of*NOS2*/rs4795067 and *NOS3*/[rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779) were found in the BD group (Pc\>0.05; [Table 3](#t3){ref-type="table"}). Furthermore, no association between the three SNPs and VKH syndrome was detected (Pc\>0.05; [Table 4](#t4){ref-type="table"}).

###### Allele and genotype frequencies of [rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067), [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) and [rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779) in BD.

  SNPs             Genotype   BD patients   Controls     P value      Pc value     OR(95%CI)
  ---------------- ---------- ------------- ------------ ------------ ------------ ------------------
  NOS2/rs4795067   AA         484(0.66)     929(0.68)    0.28         NS           0.90(0.74--1.09)
                   AG         231(0.32)     400(0.29)    0.32         NS           1.10(0.91--1.34)
                   GG         18(0.03)      30(0.02)     0.72         NS           1.12(0.62--2.02)
                   A          1199(0.82)    2258(0.83)   0.29         NS           0.92(0.78--1.08)
                   G          267(0.18)     460(0.17)    0.29         NS           1.09(0.93--1.29)
  NOS3/rs1799983   GG         509(0.69)     1027(0.76)   2.5×10^−3^   0.02         0.74(0.60--0.90)
                   GT         143(0.20)     182(0.13)    2.3×10^−4^   2.1×10^−3^   1.57(1.23--1.99)
                   TT         81(0.11)      150(0.11)    0.99         NS           1.00(0.75--1.33)
                   G          1161(0.79)    2236(0.82)   0.02         NS           0.82(0.70--0.96)
                   T          305(0.21)     482(0.18)    0.02         NS           1.22(1.04--1.43)
  NOS3/rs1800779   AA         658(0.90)     1201(0.88)   0.33         NS           1.15(0.86--1.54)
                   AG         67(0.09)      150(0.11)    0.18         NS           0.81(0.60--1.10)
                   GG         8(0.01)       8(0.01)      0.21         NS           1.86(0.70--4.99)
                   A          1383(0.94)    2552(0.94)   0.56         NS           1.08(0.83--1.42)
                   G          83(0.06)      166(0.06)    0.56         NS           0.92(0.70--1.21)

Pc, Bonferroni corrected p value; OR, odds ratio; NS, not significant; SNP, single nucleotide polymorphism.

###### Allele and genotype frequencies of rs4795067, rs1799983 and rs1800779 in VKH patients and controls.

  SNPs             Genotype   VKH patients   Controls     P value   Pc value   OR(95%CI)
  ---------------- ---------- -------------- ------------ --------- ---------- ------------------
  NOS2/rs4795067   AA         513(0.64)      929(0.68)    0.04      NS         0.83(0.69--0.10)
                   AG         261(0.33)      400(0.29)    0.12      NS         1.16(0.96--1.40)
                   GG         26(0.03)       30(0.02)     0.14      NS         1.49(0.87--2.54)
                   A          1287(0.80)     2258(0.83)   0.03      NS         0.84(0.71--0.98)
                   G          313(0.20)      460(0.17)    0.03      NS         1.19(1.02--1.40)
  NOS3/rs1799983   GG         584(0.73)      1027(0.76)   0.19      NS         0.87(0.72--1.07)
                   GT         138(0.17)      182(0.13)    0.02      NS         1.35(1.06--1.72)
                   TT         78(0.10)       150(0.11)    0.35      NS         0.87(0.65--1.16)
                   G          1306(0.82)     2236(0.82)   0.60      NS         0.96(0.82--1.12)
                   T          294(0.18)      482(0.18)    0.60      NS         1.04(0.89--1.23)
  NOS3/rs1800779   AA         729(0.91)      1201(0.88)   0.05      NS         1.35(1.01--1.81)
                   AG         68(0.09)       150(0.11)    0.06      NS         0.75(0.55--1.01)
                   GG         3(0.004)       8(0.01)      0.50      NS         0.64(0.17--2.40)
                   A          1526(0.95)     2552(0.94)   0.04      NS         1.34(1.01--1.78)
                   G          74(0.05)       166(0.06)    0.04      NS         0.75(0.56--0.99)

Pc, Bonferroni corrected p value; OR, odds ratio; NS, not significant; SNP, single nucleotide polymorphism.

Stratified analysis for *NOS3*/rs1799983 with main clinical manifestations of BD
--------------------------------------------------------------------------------

A stratified analysis was conducted to investigate the association of [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) with the main clinical manifestations of BD. They included arthritis, skin lesions, genital ulcer, positive pathergy reaction, and retinal vasculitis. We could not find a significant association of the genotype frequency of *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) with any clinical manifestation of BD ([Table 5](#t5){ref-type="table"}).

###### Main effects of [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) on clinical feature risk of BD,

  Clinical features        Genotype   BD with     BD without   P value   Pc value   OR(95%CI)
  ------------------------ ---------- ----------- ------------ --------- ---------- -------------------
  Genital ulcer                       n=410       n=323                              
                           GG         274(0.67)   235(0.73)    0.08      NS         0.75 (0.55--1.04)
                           GT         88(0.21)    55(0.17)     0.13      NS         1.33 (0.92--1.94)
                           TT         48(0.12)    33(0.10)     0.52      NS         1.17 (0.73--1.86)
                           G allele   636(0.78)   525(0.81)    0.08      NS         0.80 (0.62--1.03)
                           T allele   184(0.22)   121(0.19)    0.08      NS         1.26 (0.97--1.62)
  Skin lesions                        n=526       n=207                              
                           GG         361(0.69)   148(0.71)    0.45      NS         0.87 (0.61--1.24)
                           GT         102(0.19)   41(0.20)     0.90      NS         0.97 (0.65--1.50)
                           TT         63(0.12)    18(0.09)     0.20      NS         1.43 (0.82--2.48)
                           G allele   824(0.78)   337(0.81)    0.19      NS         0.83 (0.62--1.10)
                           T allele   228(0.22)   77(0.19)     0.19      NS         1.21 (0.91--1.62)
  Arthritis                           n=115       n=618                              
                           GG         86(0.75)    423(0.68)    0.18      NS         1.37 (0.87--2.15)
                           GT         19(0.16)    124(0.20)    0.38      NS         0.79 (0.46--1.34)
                           TT         10(0.09)    71(0.12)     0.77      NS         0.90 (0.45--1.80)
                           G allele   191(0.83)   970(0.79)    0.12      NS         1.34 (0.93--1.95)
                           T allele   39(0.17)    266(0.22)    0.12      NS         0.75 (0.51--1.08)
  Positive pathergy test              n=167       n=566                              
                           GG         120(0.72)   389(0.69)    0.44      NS         1.16 (0.79--1.70)
                           GT         33(0.20)    110(0.19)    0.93      NS         1.02 (0.66--1.58)
                           TT         14(0.08)    67(0.12)     0.21      NS         0.68 (0.37--1.25)
                           G allele   273(0.82)   888(0.78)    0.19      NS         1.23 (0.90--1.68)
                           T allele   61(0.18)    244(0.22)    0.19      NS         0.81 (0.60--1.11)
  Retinal vasculitis                  n=40        n=693                              
                           GG         27(0.67)    482(0.70)    0.78      NS         0.91 (0.46--1.80)
                           GT         10(0.25)    133(0.19)    0.37      NS         1.40 (0.67--2.94)
                           TT         3(0.08)     78(0.11)     0.46      NS         0.64 (0.19--2.12)
                           G allele   64(0.80)    1097(0.79)   0.86      NS         1.05 (0.80--1.85)
                           T allele   16(0.20)    289(0.21)    0.86      NS         0.95 (0.54--1.67)

Pc, Bonferroni corrected p value; OR, odds ratio; NS, not significant; SNP, single nucleotide polymorphism.

Discussion
==========

In this study, we examined the association between *NOS2*/[rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067), *NOS3*/ [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983), and *NOS3*/rs1800779 gene polymorphisms with BD and VKH syndrome and found that the frequency of the *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) GT genotype is significantly increased in patients with BD. Individuals with this genotype show an odds ratio of 1.57 of developing BD. An association was found only with BD and not with VKH syndrome perhaps because the immunopathogenesis of the two uveitis entities differs markedly. BD is currently seen as an autoinflammatory disease caused by an exaggerated response to microbial stimuli, whereas VKH syndrome is an autoimmune disease that is directed against melanocytes \[[@r28],[@r29]\]. Vasculitis is the main feature of BD, and the endothelial nitric oxide synthase (eNOS=NOS3) Glu298Asp polymorphism ([rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983)) may play an important role in the vascular response to inflammatory triggers in the blood vessel wall.

Comparison of NOS3/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) genotype frequencies in patients with BD uveitis with a specific extraocular symptom with those without the symptom did not reveal significant differences. This result indicates that the observed association is not restricted to a certain subgroup of BD uveitis cases. It would be interesting to study the NOS3 polymorphisms in patients with BD without uveitis to see whether the association is confined to ocular BD cases. NOS3 (eNOS) has unique functions in the eye in that it may play an important role in the breakdown of the retinal--blood barrier following an inflammatory stimulus. It may be possible that certain *NOS3 gene* polymorphisms may affect eNOS expression in ocular blood vessels. Further studies are needed to validate this hypothesis.

We chose the candidate SNPs (*NOS2*/[rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067), *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983), [rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779)) based on earlier reports concerning the association of NOS2 and NOS3 SNPs with autoimmune disease \[[@r17],[@r19]-[@r22],[@r24]\]. Our previous genome-wide association study (GWAS) and replication studies for BD were focused on SNPs with an association p value of less than 1.0×10^−4^. Although the SNPs in *NOS2* and *NOS3* did not reach the threshold p value smaller than 1.0×10^−4^, the SNPs in these two genes showed a suggestive association with BD (p\<0.05). Our findings in BD are in agreement with earlier findings from Korea and Italy \[[@r19],[@r30]\]. Analysis of [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) in 65 Korean patients with BD and 80 controls showed that the frequency of the GT genotype and T allele were significantly higher in the patients with BD than in the controls (Pc=6.0×10^−3^; Pc=6.0×10^−3^; separately) \[[@r19]\]. A study concerning [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) among 73 Italian patients with BD and 135 controls also showed that the GT genotype was significantly associated with BD (Pc=9.0×10^−5^) \[[@r30]\]. This study also showed that the T allele was significantly higher in patients with BD compared with healthy controls (Pc=6.0×10^−4^). However, several studies were not able to find an association between BD and [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) \[[@r31],[@r32]\]. The discrepancies between the studies might be due to the small sample size resulting in insufficient statistical power.

The *NOS3* gene is located on chromosome 7q35--36 and contains 26 exons \[[@r33]\]. The variant of the *NOS3* gene can result in deficient expression of NOS that may subsequently lead to disease \[[@r34]\]. Thus far, many studies have confirmed that the variants of the *NOS3* gene are closely related to several vascular diseases \[[@r35]\]. Different types of arterial or venous vasculitis as well as superficial thrombophlebitis and deep venous thrombosis have been reported as important features of BD \[[@r36]\] but were only occasionally observed in the patients in the present study. The reason is not clear but might be because we recruited patients from an ophthalmology department or that it might be caused by racial differences.

To ensure the validity of our findings, the following measures were taken. First, all participants were from a Han Chinese population, and we chose to work with a large sample size of patients, which was larger than previous studies in this field. Second, the diagnosis of patients with BD and VKH syndrome was made by the same senior ophthalmologist (Peizeng Yang), and patients with a doubtful diagnosis were eliminated from the study. Third, careful inquiry of the medical history of the controls was performed to exclude individuals with intraocular or extraocular inflammation or those who have an autoimmune disease. An interesting finding in our study was the observation that despite our large sample size we observed Hardy--Weinberg disequilibrium in [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) in the healthy controls. This phenomenon has also been described previously by others \[[@r33]\]. It has been suggested that selection pressure in [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) caused the Hardy--Weinberg disequilibrium in this SNP.

Our study has several limitations. We focused on the *NOS gene* but did not test other genes that are involved in the pathway that regulates the production of NO. Although we found that the SNP [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) may be a susceptibility factor for patients with BD in a Han Chinese population, we have not yet been able to identify a possible mechanism how this gene polymorphism affects BD. In addition, we tested only three SNPs in the *NOS2* and *NOS3* genes and found that SNP [rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983) in *NOS3* is associated with BD. As more than 100 SNPs are located in *NOS2* and *NOS3*, the association of other SNPs cannot be excluded from this study. Further studies including detailed fine mapping of the region and an analysis of functional effects must be performed to address this issue. In conclusion, our results showed that *NOS3*/[rs1799983](http://www.ncbi.nlm.nih.gov/snp/?term=rs1799983), but not *NOS2*/[rs4795067](http://www.ncbi.nlm.nih.gov/snp/?term=rs4795067) and *NOS3*/[rs1800779](http://www.ncbi.nlm.nih.gov/snp/?term=rs1800779), contributes to the genetic susceptibility to BD in a Han Chinese population.
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The TT genotype shows one band at 206 bp, and the TG genotype shows three bands at 206 bp,124 bp and 82 bp, whereas the GG genotype shows two bands at 124 bp and 82 bp. To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v22/appendices/mv-v22-311-app-1.jpg)."
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